RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) (PAYLOAD)
A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer Patients Without Life-Prolonging Therapies of Demonstrated Clinical Benefit (PAYLOAD)
Sponsor: EpicentRx, Inc.
Terminated
Sufficient patients enrolled to end study
Other terminated trials from EpicentRx, Inc.
- Brain Tumor, Pediatric · Phase PHASE1 · Jul 2024
- Carcinoma, Small Cell Lung · Phase PHASE3 · Mar 2024
- Cholangiocarcinoma · Phase PHASE2 · May 2016
- Lymphomas · Phase PHASE1 · Jan 2016
More terminations from EpicentRx, Inc.
Other Advanced Cancer trials with similar outcome
This PHASE1 trial investigates Advanced Cancer and Malignant Solid Tumor and is currently terminated or withdrawn. EpicentRx, Inc. leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Jan 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 6 earlier versions
-
Dec 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE1
-
Apr 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- EpicentRx, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .